EBOS Group Limited (EBO.NZ)
| Previous close | 37.00 |
| Open | 37.01 |
| Bid | 37.07 x 159000 |
| Ask | 34.79 x 1100 |
| Day's range | 36.81 - 37.50 |
| 52-week range | 33.66 - 46.75 |
| Volume | |
| Avg. volume | 158,798 |
| Market cap | 7.18B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 25.99 |
| EPS (TTM) | 1.44 |
| Earnings date | 20 Feb 2024 - 26 Feb 2024 |
| Forward dividend & yield | 1.14 (3.05%) |
| Ex-dividend date | 07 Sept 2023 |
| 1y target est | 38.56 |
- Reuters
UPDATE 3-NZ's EBOS not to proceed with $2.44 billion Greencross acquisition
Australasian pharmaceutical manufacturer EBOS Group said on Wednesday it would not proceed with a potential major transaction in the animal care segment, sending its shares 7% lower. The statement did not name its takeover target but a source with direct knowledge of the matter had said the company was in talks to acquire TPG Capital-backed pets and vets business Greencross. The Australian Financial Review reported that EBOS would pay A$3.75 billion ($2.44 billion) to acquire Greencross, without citing sources, and were set to raise about A$2 billion as early as Wednesday.
Simply Wall St.Is EBOS Group Limited's (NZSE:EBO) Latest Stock Performance A Reflection Of Its Financial Health?
EBOS Group's (NZSE:EBO) stock is up by a considerable 12% over the past month. Since the market usually pay for a...
- Simply Wall St.
Investors in EBOS Group (NZSE:EBO) have seen decent returns of 85% over the past five years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
